AbbVie used a dense web of 100-plus patents to insulate its blockbuster drug Humira from US competition while cutting deals with rivals that delayed the release of cheaper biosimilar versions, according to a proposed antitrust class action lawsuit.
The lawsuit, filed on Monday, March 18, in Chicago federal court, accused AbbVie of using a so-called “patent thicket” to maintain a monopoly over the US$20-billion-a-year drug, which is used to treat arthritis and other diseases.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
